A hepatocellular carcinoma–bone metastasis-on-a-chip model for studying thymoquinone-loaded anticancer nanoparticles

Sharifi, Fatemeh; Yeşil-Çeliktaş, Özlem; Kazan, Aslihan; Maharjan, Sushila; Saghazadeh, Saghi; Firoozbakhsh, Keikhosrow; Firoozabadi, Bahar; Zhang, Yu Shrike

doi:10.1007/s42242-020-00074-8

Cited by 51 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chitosan-coated PLGA NPs containing TQ enhanced cytotoxic potential when compared with surface-decorated TQ-poly(lactic co-glycolic acid) NPs and TQ alone; this was investigated through the MDA-MB-231 and MCF-7 cell lines [ 180 ]. The antimetastatic potential of TQ was enhanced by chitosan nanoparticles against HepG2 cell lines through longer duration inhibitory actions when compared with free TQ [ 181 ]. TQ-NLC-NPs accumulated in cancer cells and inhibited their proliferation through time and dose-dependent modulation in the cellular morphology, as investigated in HepG2 cancer cells [ 182 ].…”

Section: Neoplasm and Its Pathogenesismentioning

confidence: 99%

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

Cancer causes a considerable amount of mortality in the world, while arthritis is an immunological dysregulation with multifactorial pathogenesis including genetic and environmental defects. Both conditions have inflammation as a part of their pathogenesis. Resistance to anticancer and disease-modifying antirheumatic drugs (DMARDs) happens frequently through the generation of energy-dependent transporters, which lead to the expulsion of cellular drug contents. Thymoquinone (TQ) is a bioactive molecule with anticancer as well as anti-inflammatory activities via the downregulation of several chemokines and cytokines. Nevertheless, the pharmacological importance and therapeutic feasibility of thymoquinone are underutilized due to intrinsic pharmacokinetics, including short half-life, inadequate biological stability, poor aqueous solubility, and low bioavailability. Owing to these pharmacokinetic limitations of TQ, nanoformulations have gained remarkable attention in recent years. Therefore, this compilation intends to critically analyze recent advancements in rheumatoid arthritis and cancer delivery of TQ. This literature search revealed that nanocarriers exhibit potential results in achieving targetability, maximizing drug internalization, as well as enhancing the anti-inflammatory and anticancer efficacy of TQ. Additionally, TQ-NPs (thymoquinone nanoparticles) as a therapeutic payload modulated autophagy as well as enhanced the potential of other drugs when given in combination. Moreover, nanoformulations improved pharmacokinetics, drug deposition, using EPR (enhanced permeability and retention) and receptor-mediated delivery, and enhanced anti-inflammatory and anticancer properties. TQ’s potential to reduce metal toxicity, its clinical trials and patents have also been discussed.

show abstract

Section: Neoplasm and Its Pathogenesismentioning

confidence: 99%

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Sharif et al developed an HCC-bone metastasis-on-achip system which models key aspects in the process of liver cancer invasion. This platform was used for studying the inhibitory effect of nanoparticle-encapsulated thymoquinone on the migration of HCC cells into the bone [111].…”

Section: Hcc-on-a-chipmentioning

confidence: 99%

Experimental Models of Hepatocellular Carcinoma—A Preclinical Perspective

Blidișel

Marcovici

Coricovac

et al. 2021

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), the most frequent form of primary liver carcinoma, is a heterogenous and complex tumor type with increased incidence, poor prognosis, and high mortality. The actual therapeutic arsenal is narrow and poorly effective, rendering this disease a global health concern. Although considerable progress has been made in terms of understanding the pathogenesis, molecular mechanisms, genetics, and therapeutical approaches, several facets of human HCC remain undiscovered. A valuable and prompt approach to acquire further knowledge about the unrevealed aspects of HCC and novel therapeutic candidates is represented by the application of experimental models. Experimental models (in vivo and in vitro 2D and 3D models) are considered reliable tools to gather data for clinical usability. This review offers an overview of the currently available preclinical models frequently applied for the study of hepatocellular carcinoma in terms of initiation, development, and progression, as well as for the discovery of efficient treatments, highlighting the advantages and the limitations of each model. Furthermore, we also focus on the role played by computational studies (in silico models and artificial intelligence-based prediction models) as promising novel tools in liver cancer research.

show abstract

“…Conversely, multiple-cell-type tumor-on-a-chip platforms (e.g., cancer, endothelial, stromal, and immune cells) have been used to investigate the specific crosstalk between different cell populations in the tumor microenvironments such as signaling cascades, tumor angiogenesis, and metastasis pathways ( Kolesky et al, 2014 ; Grolman et al, 2015 ; Sharifi et al, 2020 ; Cabon et al, 2021 ). Alternatively, 3D-bioprinted compartmented multiple-cell constructs have been used to create paracrine loops for studying cancer cell extravasation into the bloodstream and analyze metastatic progression through trans-endothelial migration ( Kolesky et al, 2014 ; Wang et al, 2018c ; Li J. et al, 2020 ).…”

Section: Tackling Current Biomedical Challenges With Frontier Technologiesmentioning

confidence: 99%

Tackling Current Biomedical Challenges With Frontier Biofabrication and Organ-On-A-Chip Technologies

Celikkin

Presutti

Maiullari

et al. 2021

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

In the last decades, biomedical research has significantly boomed in the academia and industrial sectors, and it is expected to continue to grow at a rapid pace in the future. An in-depth analysis of such growth is not trivial, given the intrinsic multidisciplinary nature of biomedical research. Nevertheless, technological advances are among the main factors which have enabled such progress. In this review, we discuss the contribution of two state-of-the-art technologies–namely biofabrication and organ-on-a-chip–in a selection of biomedical research areas. We start by providing an overview of these technologies and their capacities in fabricating advanced in vitro tissue/organ models. We then analyze their impact on addressing a range of current biomedical challenges. Ultimately, we speculate about their future developments by integrating these technologies with other cutting-edge research fields such as artificial intelligence and big data analysis.

show abstract

A hepatocellular carcinoma–bone metastasis-on-a-chip model for studying thymoquinone-loaded anticancer nanoparticles

Cited by 51 publications

References 26 publications

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

Experimental Models of Hepatocellular Carcinoma—A Preclinical Perspective

Tackling Current Biomedical Challenges With Frontier Biofabrication and Organ-On-A-Chip Technologies

Contact Info

Product

Resources

About